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Summary. Hepatitis C is a major co-morbidity
among patients with haemophilia who received
inadequately or non-virus-inactivated clotting factor
concentrates before 1992. The objectives of this
study were to investigate the prevalence of hepatitis
C and the use of antiviral therapies during the last
decade among patients with haemophilia in the
Netherlands. We performed a cross-sectional study
and a questionnaire was sent to all 1519 patients
known with haemophilia in the Netherlands
between 2001 and 2002. The study population
for the present study consisted of 771 patients who
had received clotting factor products before 1992
of whom 638 reported their hepatitis C status.
In total, 441 of the 638 (68%) patients ever had
a positive test for hepatitis C virus (HCV); 344
patients (54%) had a current infection, and 97
(15%) had cleared the virus. Among 344 patients
currently HCV infected, 111 (32%) had received
treatment for hepatitis C, while 34% (33/97) of
patients with an infection in the past had been
treated for hepatitis C. In 2002 the prevalence of
hepatitis C among patients with haemophilia who
received clotting factor products before 1992 was
54%. The majority of patients with a current HCV
infection had not been treated with antiviral
therapy.
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Introduction
Haemophilia is an X-linked bleeding disorder
caused by a partial or complete lack of clotting
factor activity: factor VIII in haemophilia A and
factor IX in haemophilia B. Since the 1960s
haemophilia patients have received intravenous fac-
tor VIII and IX replacement therapy [1]. In the
following years it became apparent that viruses like
human immunodeficiency virus (HIV) and hepatitis
C virus (HCV), formerly known as non-A non-B
hepatitis, were transmitted due to transfusion of
infected plasma products [2,3]. Patients treated with
large pool products were infected with HCV in
98%, whereas patients treated with cryoprecipitate
were infected in 66% of the cases [4]. In the early
1990s, methods were developed to adequately inac-
tivate HCV and subsequently donor screening for
HCV was introduced, resulting in HCV safe clotting
products [4–6].
Once infected, about 10–20% of the patients are
able to clear the virus spontaneously, while the others
develop a chronic carrier state [7–9]. Untreated HCV
infection may progress to liver fibrosis, cirrhosis or
hepatocellular carcinoma [10,11]. Liver disease
caused by HCV is now recognized as an important
cause of morbidity in haemophilia patients [12].
Treatment for non-A non-B hepatitis became avail-
able in 1986 [13,14]. Today pegylated interferon
(Peg-IFN) in combination with ribavirin is the most
effective therapy for hepatitis C [15]. Success of
therapy is mainly dependent on genotype and viral
load [16]. Antiviral drugs cause side effects like
anaemia, neutropenia, depression and flu-like sym-
ptoms in the majority of the patients [17–19].
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Little or no information is available on the current
prevalence of hepatitis C and antiviral treatment
history among patients who have received inad-
equately or non-virus inactivated clotting factor
concentrates before 1992. We therefore investigated
the prevalence of hepatitis C infection and assessed
the use of antiviral therapy among patients with
haemophilia in the Netherlands.
Materials and methods
Setting
Data for the present study were collected within the
last survey of a series initiated by Veltkamp in 1972
[20]. Since then nationwide surveys were repeated in
1978, 1985, 1992 and in 2001 [21–24]. These studies
aimed at assessing the medical and social conse-
quences of haemophilia in the Netherlands. In 2001,
postal questionnaires were sent to all 1519 patients
known with haemophilia in the Netherlands, who
were either registered at the Netherlands Hemophilia
Patients Society, at the haemophilia treatment
centres or known from previous surveys. In this last
survey items on hepatitis C were added for the first
time.
Data
The study population consisted of patients who were
treated with clotting factor products before 1992 and
who reported their hepatitis C status. These patients
were potentially at risk for HCV infection because
they were treated with non-virus inactivated or
inadequately inactivated clotting factor concentrates.
Severity of haemophilia was defined by the percent-
age of factor VIII or factor IX clotting activity: severe
haemophilia <1%, moderate haemophilia 1–5%,
and mild haemophilia 5–40% clotting factor activity.
Reported type and severity of haemophilia were
verified with information from the treatment centres.
In addition, data on haemophilia type and severity of
non-responders were obtained from treatment cen-
tres or from the previous questionnaire performed in
1992. Haemophilia type and severity of 346 non-
responders were similar to those in the study
population. Items on hepatitis C and HIV were
obtained from the questionnaire. Information on the
hepatitis B status was not collected.
To assess the validity of the self-reported items on
hepatitis C, a random sample of 92 patients (14%)
was taken from the two largest participating centres
verifying their reported hepatitis C status with
information from their treating haematologist.
Statistics
Infection with HCV was defined as three possible
status: never infected with HCV, HCV infection
cleared and chronic hepatitis C. Never infected with
HCV was defined as negative for both HCV anti-
bodies and HCV-RNA in serum. A cleared HCV
infection or infection in the past was defined as
positive for HCV antibodies but negative for HCV-
RNA. Chronic hepatitis Cwas defined as positive for
both HCV antibodies and HCV-RNA. In addition,
ever infected with HCV was defined as positive for
HCV antibodies, regardless of the HCV RNA result.
To study risk of infection according to period of
treatment, a sub-analysis was performed comparing
infection rates between patients first treated before
1985 with patients first treated between 1985 and
1992. Patients with incomplete treatment history
were excluded for this sub-analysis.
The HCV status according to type and severity of
haemophilia was compared by using the chi-square
test. Mean values with 95% confidence intervals of
age according to severity of haemophilia and HCV
infection status were calculated.
Results
A flow chart of the selection of patients for this study
is shown in Fig. 1. The response to the questionnaire
was 1066 of 1519 (70%). General characteristics of
the participants are shown in Table 1.
Hepatitis C
Patients treated with clotting products before 1992
A total of 771 patients were at risk for HCV
infection (i.e. treated before 1992); 599 were already
treated with clotting products before 1985, 136 were
treated exclusively between 1985 and 1992, whereas
36 patients reported to have been treated before
1992 but not whether they were also exposed to
clotting products before 1985. 638 of these 771
patients reported their HCV status. Among the 133
patients at risk without a HCV test result, 68% had
mild haemophilia.
In the verification sample, 92% (85/92) reported
their hepatitis C status correctly; 96% of patients
with an HCV infection and 88% of patients with a
cleared infection or those who where never infected.
Among 638 patients treated with clotting factor
products before 1992 and tested for HCV, 441
(68%) ever had an anti-HCV positive test; 344
(54%) reported to be currently infected with HCV,
97 (15%) reported an infection in the past and
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197 patients (31%) had never been infected. No
infections with HCV occurred in patients who were
treated after 1992 only.
HCV infection was related to type of haemophilia;
patients with haemophilia B had been infected more
often than those with type A (84% vs. 67%,
P < 0.01). Among patients at risk for HCV transmis-
sion, patients with severe haemophilia had the
highest prevalence of hepatitis C (severe 65%,
moderate 53%, mild 37%, P < 0.001).
The mean age of patients differed according to
severity of haemophilia and HCV status; patients
with severe haemophilia, who were never infected,
were younger [mean age 23 years, 95% confidence
interval (CI) 19–28] than both patients with severe
haemophilia who cleared HCV (37 years, CI 33–41),
and those currently infected (43 years, CI 41–45).
Infection rate of HCV according to treatment period
Although HCV-inactivating steps were applied since
1985, risk of HCV infection was not completely
eliminated; 523 of 599 patients treated before 1985
and 95 of 136 patients treated during 1985–92
reported their HCV status. Among patients treated
before 1985, 62% reported to be currently infected,
while 17% cleared HCV. In contrast, the proportion
of patients with chronic HCV infection was only
18%, with 7% clearing HCV and 75% never
infected in those first treated between 1985 and
1992.
HIV infection
The prevalence of HIV infection among patients
treated before 1985 and reporting their HIV status
was 5% (28/523).
Treatment of hepatitis C
Among the 344 patients with a current HCV
infection, 68% (233) had not been treated with
antiviral drugs. The main reasons for refraining from
therapy were shrinking from side effects (46%),
normal liver function tests (45%) and expected low
effectivity (35%). Other reported reasons were:
doctor not convinced of benefit of treatment
(19%), treatment not discussed by doctor (18%)
and lack of time among patients (9%). Over the last
decade, the proportion of patients having been
treated, is increasing (Fig. 2).
Treatment for HCV was completed among 128
patients and successful treatment was reported in
26% (33/128). Sixteen patients were currently on
combination therapy of IFN and ribavirin. Among
patients who finished therapy, 57 patients were
treated with IFN monotherapy, 51 patients with
the combination of IFN and ribavirin, while 13
patients were first treated with monotherapy and
Not tested for HCV, n = 57
Did not know test result, n = 56
No response, n = 11
No test result
n = 9
Current infection
with HCV
n = 344
HCV infection
in the past
n = 97
Never infected
with HCV
n = 197
HCV test result
n = 638
Tested for HCV
n = 647
Treated with
clotting factor products
before 1992
n = 771
70% response
to questionnaire
n = 1066
All known haemophilia
patients in
the Netherlands
n = 1519
Fig. 1. Flowchart of selection of study population.
Table 1. Patient characteristics.*
Total number of patients 638
Age in years 41 (10–87)
Haemophilia type
A 557 (87)
B 81 (13)
Severity of haemophilia
Mild 211 (33)
Moderate 112 (18)
Severe 315 (49)
Patients treated before 1985 523 (82)
HIV positive 28 (5)
Patients treated before 1992 638
Anti HCV positive 441 (68)
HCV RNA positive 344 (54)
*Information of patients treated before 1992 with a reported HCV
test result. Values are medians (range) or numbers (percentage).
At risk for HIV infection due to not adequately or non-virus-
inactivated clotting factor products.
At risk for HCV infection due to not adequately or non-virus-
inactivated clotting factor products.
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later retreated with combination therapy. Seven
patients did not remember their treatment regimen.
Reported side effects of antiviral therapy was 84%
(121/144). Fatigue (78%), flu-like symptoms (73%),
and depressive symptoms (46%) were most fre-
quently reported. In 15% of treated patients therapy
was discontinued because of side effects.
Discussion
We report on a nationwide survey on the current
prevalence of hepatitis C in haemophilia patients. Of
771 patients at risk for HCV infection, 638 reported
their hepatitis C status. Fifty-four per cent of tested
patients reported to be currently infected with HCV,
of whom 32% had been treated with antiviral
therapy.
We performed a cross-sectional study to assess the
prevalence of hepatitis C infection among patients
with haemophilia in the Netherlands and to examine
the use of antiviral treatment. To appreciate our
findings some limitations need to be discussed. First,
the response rate to the questionnaire was 70%, and
selection bias cannot be ruled out. Non-responders to
the questionnaire may have been less severely affec-
ted, therefore failing to see the need for a survey in
this population. This may have led to an overesti-
mation of the prevalence of hepatitis C. However,
percentages of type and severity were similar in
responders and non-responders, rendering bias less
likely.
Secondly, self-reported data may be unreliable. We
therefore performed a validation study and found
that these self-reported data were highly reliable,
confirming previous observations that most patients
with haemophilia are well informed about their
disease and its complications [21].
In this study, 68% of all tested patients potentially
exposed to insufficiently viral-inactivated clotting
factor products had ever been infected with HCV
and 54% of them reported a current HCV infection.
The prevalence of hepatitis C in this population is
similar to that reported by others [4,9,25]. As
expected, the prevalence was highest among patients
with severe haemophilia due to a higher number of
exposures to clotting products than patients with
mild or moderate disease. Haemophilia B was
associated with a higher HCV infection rate (84%
vs. 67%) due to exclusive treatment with large pool
plasma products, whereas patients with haemophilia
A were in many cases exclusively treated with small
pool cryoprecipitate [26]. Confirming data in a
Dutch study on 316 patients, reported HCV infection
rates of 66% and 98% in patients exclusively treated
with small pool cryoprecipitate and patients treated
with large pool products, respectively [4]. In addi-
tion, the proportion of patients with severe haemo-
philia was higher among patients with haemophilia B
than in those with haemophilia A (58% vs. 48%),
with concomitant higher exposure rates to poten-
tially unsafe clotting factor products.
In our study, we found that the risk of HCV
transmission was lower among younger patients.
This may be explained by the lower number of
exposures and the introduction of dry heat treatment
(up to 68 C) in 1985. Although completely effective
for HIV, this method of viral inactivation did not
eliminate HCV infection risk, but resulted in a
reduction of HCV load only [27]. This is also shown
in our study, in which patients exclusively treated
with clotting products between 1985 and 1992 had a
lower risk of HCV infection than patients treated
before 1985. Although this risk was decreased, HCV
transmission was not eliminated. Finally, donor
screening, pasteurization, steam heat treatment and
chemical viral inactivation through the combination
of solvent and detergent methods were introduced
on a large scale, eliminating transmission of HCV
completely in 1992 [6,28,29].
Although there has been a trend towards starting
treatment of HCV infection, only 32% of the HCV-
infected patients reported use of antiviral therapy,
with a success rate of 26%. The main reasons for
refraining from antiviral therapy were expected low
effectivity of therapy, normal liver function tests and
expected side effects. The argument of low expected
effectivity loses its strength as treatment with PegIFN
and ribavirin results in a sustained response in 50–
90% in treatment-naive patients dependent on viral
genotype [18]. It has been suggested that refraining
from therapy in case of normal liver function tests
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Fig. 2. Cumulative percentage of all HCV-infected patients with
haemophilia treated with antiviral therapy during the last decade.
Considering a spontaneous clearance of 15%, the maximum
cumulative percentage would be 85%.
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may be appropriate in patients with genotype 1 and 4
with normal histology at liver biopsy [30]. But this is
inappropriate in patients with HCV genotype 2, 3
and 5, of whom 90% will achieve a sustained
response.
Fatigue, flu-like symptoms and depression were the
most frequently reported adverse events of antiviral
therapy; this is in accordance with other reports [17].
Depression has been a common indication for dose
reduction or even discontinuation of therapy [17,31].
Discontinuation of therapy due to adverse effects
was reported in 15% in this study and was similar to
that reported by others [18,19,32,33].
The reported reasons for refraining from antiviral
therapy indicate that there are still uncertainties
about long-term complications of hepatitis C and
effectivity of antiviral therapy. Therefore, patients
need to be fully informed about HCV infection, its
consequences, possibilities of treatment and its
effectivity.
In summary, this study shows that hepatitis C is
still a major comorbidity in the Dutch population of
haemophilia patients and only a minority of patients
with an HCV infection has been treated.
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